<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344979</url>
  </required_header>
  <id_info>
    <org_study_id>ShenyangSunshine</org_study_id>
    <nct_id>NCT02344979</nct_id>
  </id_info>
  <brief_title>The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC</brief_title>
  <official_title>The Study of rHuTPO/rHuIL-11 in the Treatment for Chemotherapy-induced Thrombocytopenia in Patients With NSCLC Receiving Gemcitabine and Cisplatin or Carboplatin Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenyang Sunshine Pharmaceutical Co., LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenyang Sunshine Pharmaceutical Co., LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To evaluate the efficacy and safety of rHuTPO/rHuIL-11 in the treatment for&#xD;
      chemotherapy-induced thrombocytopenia in patients with NSCLC receiving gemcitabine and&#xD;
      cisplatin or carboplatin chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inclusion Criteria:&#xD;
&#xD;
        1. Patients aged 18 years -75 years, male or female;&#xD;
&#xD;
        2. histologically or cytologically confirmed non-small cell lung cancer;&#xD;
&#xD;
        3. consistent with the indication of chemotherapy&#xD;
&#xD;
        4. the decrease of platelets appeared in the screen chemotherapy period and the platelet&#xD;
           count is less than 50 * 109/ L;&#xD;
&#xD;
        5. the expected survival was more than 3 months;&#xD;
&#xD;
        6. patients must have the ability to understand and the willingness to sign a written&#xD;
           informed consent;&#xD;
&#xD;
        7. to be able to follow the study and follow-up procedures&#xD;
&#xD;
      Exclusion Criteria:&#xD;
&#xD;
        1. pregnant or lactating women;&#xD;
&#xD;
        2. patients who had severe allergic history on biological preparation;&#xD;
&#xD;
        3. the existing serious acute infection without control;&#xD;
&#xD;
        4. Patients receiving radiotherapy;&#xD;
&#xD;
        5. more than 3 metastatic tumor of bone were found in the screening period, and the&#xD;
           platelet count did not restore to 100 * 109/ L on the screening period on the&#xD;
           seventeenth day of the screening period;&#xD;
&#xD;
        6. with a history of pulmonary embolism, myocardial infarction patients, thrombus history&#xD;
           of thrombosis or activity in the past 3 months;&#xD;
&#xD;
        7. Sepsis, disseminated intravascular coagulation (DIC); hypersplenism or any other illness&#xD;
           sickness that can exacerbate thrombocytopenia appeared in the previous cycles of&#xD;
           chemotherapy;&#xD;
&#xD;
        8. tumor metastasis was found in the central nervous system;&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2009</start_date>
  <completion_date type="Anticipated">June 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The mean minimal and maximal platelet count after rHuTPO or rHuIL-11.</measure>
    <time_frame>28days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to achieve platelet count ≥75×109/L and ≥100×109/L after rHuTPO or rHuIL-11. The duration of platelet count &lt;50×109/L after rHuTPO or rHuIL-11.</measure>
    <time_frame>28days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The number of platelet transfusions after rHuTPO or rHuIL-11.</measure>
    <time_frame>28days</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Group rHuTPO</arm_group_label>
    <description>Patients were treated with recombinant human thrombopoietin(rHuTPO)on d2,d4,d6,d9 of chemotherapy cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group rHuIL-11</arm_group_label>
    <description>Patients were treated with recombinant human interleukin-11(rHuIL-11)on d9-d15 after chemotherapy.</description>
  </arm_group>
  <biospec_descr>
    <textblock>
      Randomized, open label, controlled, parallel, multi-center Study&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with NSCLC for whom treatment with gemcitabine and cisplatin or carboplatin,and&#xD;
        Platele counts ≤ 50×109/L during Screening chemo cycle&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age&gt;18 years, Male or females&#xD;
&#xD;
          -  Patients with NSCLC for whom treatment with gemcitabine and cisplatin or carboplatin&#xD;
&#xD;
          -  Platele counts ≤ 50×109/L during Screening chemo cycle&#xD;
&#xD;
          -  ECOG PS score is ≤ 2&#xD;
&#xD;
          -  The predicted life expectancy ≥3 months&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Known history of severe anaphylactic reaction to biologics&#xD;
&#xD;
          -  Uncontrolled severe infection&#xD;
&#xD;
          -  History of bone or central nervous system metastasis&#xD;
&#xD;
          -  History of platelet disorder&#xD;
&#xD;
          -  Active bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Shanghai Chest Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.3sbio.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>January 2015</verification_date>
  <study_first_submitted>January 18, 2015</study_first_submitted>
  <study_first_submitted_qc>January 22, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <last_update_submitted>January 22, 2015</last_update_submitted>
  <last_update_submitted_qc>January 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>Chemotherapy</keyword>
  <keyword>thrombocytopenia</keyword>
  <keyword>rhTPO</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

